Selectively promiscuous opioid ligands: Discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity

Journal of Medicinal Chemistry

Volumn 57, Issue 10, 2014, Pages 4049-4057

  Kumar, Vinod ^a,e   Ridzwan, Irna E ^a   Grivas, Konstantinos ^c   Lewis, John W ^a   Clark, Mary J ^b   Meurice, Claire ^b   Jimenez Gomez, Corina ^b   Pogozheva, Irina ^d   Mosberg, Henry ^d   Traynor, John R ^b   Husbands, Stephen M ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF MICHIGAN   (United States)

^e CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHANOMORPHINAN 7 YL) 1' (2 PYRIDYL)ETHAN 1' OL; 1' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHANOMORPHINAN 7 YL) 1' PHENYLETHAN 1' OL; 1' (4,5 EPOXY 7,8 DIHYDRO 3 HYDROXY 6 METHOXY 17 CYCLOPROPYLMETHYL 6,14 ETHENOMORPHINAN 7 YL) 1' PHENYLMETHANOL; BUPRENORPHINE; DELTA OPIATE RECEPTOR; ETHYLKETAZOCINE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; N CYCLOPROPYLMETHYLNORISONEPENTHOL; N CYCLOPROPYLMETHYLNORNEPENTHOL; NOCICEPTIN; OPIATE ANTAGONIST; PHENYL GROUP; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY;

ANIMALS; BUPRENORPHINE; DRUG DISCOVERY; LIGANDS; MICE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901247101     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401964y     Document Type: Article

References (29)

1. Lewis, J. W.; Husbands, S. M. The orvinols and related opioids - high affinity ligands with diverse efficacy profiles Curr. Pharm. Des. 2004, 10, 717-732
2. Bentley, K. W.; Hardy, D. G. Novel analgesics and molecular rearrangements in morphine-thebaine group. 3. Alcohols of 6,14- endo -ethenotetrahydrooripavine series and derived analogs of n -allylnormorphine and -norcodeine J. Am. Chem. Soc. 1967, 89, 3281-3292
3. Bentley, K. W.; Hardy, D. G.; Meek, B. Novel analgesics and molecular rearrangements in morphine-thebaine group. 2. Alcohols derived from 6,14- endo -etheno- and 6,14- endo -ethanotetrahydrothebaine J. Am. Chem. Soc. 1967, 89, 3273-3280
4. Lewis, J. W.; Bentley, K. W.; Cowan, A. Narcotic analgesics and antagonists Annu. Rev. Pharmacol. 1971, 11, 241-270
5. Lewis, J. W. Buprenorphine: Medicinal Chemistry. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid; Cowan, A.; Lewis, J. W., Eds.; Wiley-Liss, Inc.: New York, 1995; pp 3-16.
6. Hans, G. H. Buprenorphine in the Treatment of Neuropathic Pain. In Research and Development of Opioid-Related Ligands; ACS Symposium Series, 1131; American Chemical Society: Washington, DC, 2013; pp 103-123.
7. Mogali, S.; Comer, S. D. Treatment of Pain and Opioid Abuse. In Research and Development of Opioid-Related Ligands; ACS Symposium Series, 1131; American Chemical Society: Washington, DC, 2013; pp 39-60.
8. Husbands, S. M. Buprenorphine and Related Orvinols. In Research and Development of Opioid-Related Ligands; ACS Symposium Series, 1131; American Chemical Society: Washington, DC, 2013; pp 127-144.
9. Cowan, A. Buprenorphine: the basic pharmacology revisited J. Addict. Med. 2007, 1, 68-72
10. Lutfy, K.; Cowan, A. Buprenorphine: a unique drug with complex pharmacology Curr. Neuropharmacol. 2004, 2, 395-402
11. Budd, K.; Raffa, R. B. Buprenorphine: The Unique Opioid Analgesic: Pharmacology and Clinical Application; Georg Thieme: Berlin, 2005; p 134.
12. Lewis, J. W. Ring C-bridged derivatives of thebaine and oripavine Adv. Biochem. Psychopharmacol. 1973, 8, 123-136
13. Greedy, B. M.; Bradbury, F.; Thomas, M. P.; Grivas, K.; Cami-Kobeci, G.; Archambeau, A.; Bosse, K.; Clark, M. J.; Aceto, M.; Lewis, J. W.; Traynor, J. R.; Husbands, S. M. Orvinols with mixed kappa/mu opioid receptor agonist activity J. Med. Chem. 2013, 56, 3207-3216
14. Anh, N. T.; Eisenstein, O. Theoretical interpretation of 1-2 asymmetric induction importance of anti-periplanarity Nouv. J. Chim. 1977, 1, 61-70
15. Spagnolo, B.; Calo, G.; Polgar, W. E.; Jiang, F.; Olsen, C. M.; Berzetei-Gurske, I.; Khroyan, T. V.; Husbands, S. M.; Lewis, J. W.; Toll, L.; Zaveri, N. T. Activities of mixed NOP and mu-opioid receptor ligands Br. J. Pharmacol. 2008, 153, 609-619
16. Lee, K. O.; Akil, H.; Woods, J. H.; Traynor, J. R. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors Eur. J. Pharmacol. 1999, 378, 323-330
17. Shaw, J. S.; Rourke, J. D.; Burns, K. M. Differential sensitivity of antinociceptive tests to opioid agonists and partial agonists Br. J. Pharmacol. 1988, 95, 578-584
18. Huang, P.; Kehner, G. B.; Cowan, A.; Liu-Chen, L. Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist J. Pharmacol. Exp. Ther. 2001, 297, 688-695
19. Cami-Kobeci, G.; Polgar, W. E.; Khroyan, T. V.; Toll, L.; Husbands, S. M. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine J. Med. Chem. 2011, 54, 6531-6537
20. Yu, G.; Yan, L.-D.; Li, Y.-L.; Wen, Q.; Dong, H.-J.; Gong, Z.-H. TH-030418: a potent long-acting opioid analgesic with low dependence liability Naunyn-Schmiedeberg's Arch. Pharmacol. 2011, 384, 125-131
21. Anand, J. P.; Purington, L. C.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models Chem. Biol. Drug Des. 2012, 80, 763-770
22. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X.-P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
23. Pogozheva, I. D.; Przydzial, M. J.; Mosberg, H. I. Homology modeling of opioid receptor-ligand complexes using experimental constraints AAPS J. 2005, 7, E434-448
24. Husbands, S. M.; Lewis, J. W. Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine J. Med. Chem. 2000, 43, 139-141
25. Coop, A.; Norton, C. L.; Berzetei-Gurske, I.; Burnside, J.; Toll, L.; Husbands, S. M.; Lewis, J. W. Structural determinants of opioid activity in the orvinols and related structures: ethers of orvinol and isoorvinol J. Med. Chem. 2000, 43, 1852-1857
26. Hutchins, C. W.; Rapoport, H. Analgesics of the orvinol type 19-deoxy and 6,20-epoxy derivatives J. Med. Chem. 1984, 27, 521-527
27. Marton, J.; Simon, C.; Hosztafi, S.; Szabó, Z.; Márki, á.; Borsodi, A.; Makleit, S. New nepenthone and thevinone derivatives Bioorg. Med. Chem. 1997, 5, 369-382
28. Broadbear, J. H.; Sumpter, T. L.; Burke, T. F.; Husbands, S. M.; Lewis, J. W.; Woods, J. H.; Traynor, J. R. Methcinnamox is a potent, long-lasting and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, β-FNA and β-chlornaltrexamine Pharmacol. Exp. Ther. 2000, 294, 933-940
29. Jutkiewicz, E. M.; Wood, S. K.; Houshyar, H.; Hsin, L.-W.; Rice, K. C.; Woods, J. H. The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats Psychopharmacol. 2005, 215-223